Diagnosis of Gastric Precancerous Lesions by a Blood Test GastroPanel in Patients With Increased Gastric Cancer Risk (GASTRO-PRA)

Nantes University Hospital (NUH)

Status

Completed

Conditions

Gastric Precancerous Lesions

Gastric Cancer

Treatments

Other: blood samples analysis

Study type

Interventional

Funder types

Other

Identifiers

NCT02624271

RC14_0371

Details and patient eligibility

About

Despite the declining incidence, gastric cancer (GC) remains the second leading cause of cancer death worldwide. In France, it is the second digestive cancer with 7,000 new cases per year. It is now well demonstrated that patients with H. pylori infection, atrophic gastritis and intestinal metaplasia, have a high risk of developing GC. It is therefore important to detect these pre-neoplastic lesions at an early stage to improve patients prognosis.

Thus, the aim of this project is to investigate the possible screening of gastric precancerous lesions by a blood test (GastroPanel®) in France, in patients with oesophagogastroduodenoscopy (EGD) prescription.

Enrollment

2,000 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients undergoing oesophagogastroduodenoscopy (EGD) according to usual care
Patients with increased risk of gastric cancer (at least one of the following criteria):
- age > 50 years,
- family cases of gastric cancer,
- known precancerous lesions,
- Biermer disease,
- H. Pylori infection,
- genetic predisposition (ex: Lynch syndrome),
- MALT lymphoma,
- dyspepsia.
Subjects affiliated with an appropriate social security system

Exclusion criteria

Subjects with known active cancer
Pregnancy
Patients receiving proton-pump inhibitors
Conditions that may interfere with the study objectives according to the investigator